Pompe Disease
Introduction
Pompe Disease is a progressive neurodegenerative disorder characterized by the gradual loss of neuronal function. This page provides comprehensive information about the disease, including its pathophysiology, clinical presentation, diagnosis, and current therapeutic approaches.
Pompe disease (Glycogen Storage Disease Type II, Acid Maltase Deficiency) is a rare autosomal recessive lysosomal storage disorder caused by deficiency of the enzyme acid alpha-glucosidase (GAA), leading to accumulation of glycogen in lysosomes primarily in skeletal muscle, cardiac muscle, and nervous system[1]. The disease is classified as both a neuromuscular disorder and a neurodegenerative disease due to its effects on motor [neurons](/entities/neurons) and peripheral nerves[2].
Overview
Pompe disease represents a spectrum of severity from infantile-onset to late-onset forms, with varying degrees of central nervous system involvement. The disease results from mutations in the GAA gene leading to deficiency of acid alpha-glucosidase, a lysosomal enzyme responsible for breaking down glycogen[3]. This enzymatic deficiency causes glycogen to accumulate within lysosomes, leading to cellular dysfunction and tissue damage across multiple organ systems[4].
...Pompe Disease
Introduction
Pompe Disease is a progressive neurodegenerative disorder characterized by the gradual loss of neuronal function. This page provides comprehensive information about the disease, including its pathophysiology, clinical presentation, diagnosis, and current therapeutic approaches.
Pompe disease (Glycogen Storage Disease Type II, Acid Maltase Deficiency) is a rare autosomal recessive lysosomal storage disorder caused by deficiency of the enzyme acid alpha-glucosidase (GAA), leading to accumulation of glycogen in lysosomes primarily in skeletal muscle, cardiac muscle, and nervous system[1]. The disease is classified as both a neuromuscular disorder and a neurodegenerative disease due to its effects on motor [neurons](/entities/neurons) and peripheral nerves[2].
Overview
Pompe disease represents a spectrum of severity from infantile-onset to late-onset forms, with varying degrees of central nervous system involvement. The disease results from mutations in the GAA gene leading to deficiency of acid alpha-glucosidase, a lysosomal enzyme responsible for breaking down glycogen[3]. This enzymatic deficiency causes glycogen to accumulate within lysosomes, leading to cellular dysfunction and tissue damage across multiple organ systems[4].
The neurodegenerative aspects of Pompe disease include motor neuron degeneration in the spinal cord, similar to spinal muscular atrophy (SMA), as well as white matter changes in the brain and cognitive fatigue in late-onset patients[5]. Research has shown that GAA deficiency affects not only muscle tissue but also neurons in both the peripheral and central nervous systems[6].
Genetics and Molecular Basis
- Gene: GAA (Acid Alpha-Glucosidase) located on chromosome 17q25.2
- Inheritance: Autosomal recessive
- Mutations: Over 200 pathogenic variants identified in the GAA gene
- Enzyme deficiency: Acid alpha-glucosidase (GAA), which normally breaks down lysosomal glycogen
The GAA gene encodes a 952-amino acid protein that is targeted to lysosomes via a signal peptide[7]. Pathogenic variants include nonsense mutations, missense mutations, splice-site mutations, and deletions that result in reduced or absent enzyme activity. Genotype-phenotype correlations exist, with certain mutations associated with the infantile-onset form while others correlate with late-onset disease[8].
Common pathogenic variants include:
- c.525delT (p.D176fs*14)
- c.1634C>T (p.P545L)
- c.2065G>A (p.G689S)
- IVS1 (-13T>G) splice mutation
Pathophysiology
The disease mechanism involves multiple interconnected pathways[9]:
Enzyme deficiency: Lack of functional GAA leads to failure of lysosomal glycogen breakdown
Glycogen accumulation: Glycogen-filled vacuoles accumulate in:
- Skeletal muscle fibers (type II fibers preferentially affected)
- Cardiac muscle cells (cardiomyopathy)
- Motor neurons in the spinal cord
- Smooth muscle
- Liver and kidney (less affected)
3.
Cellular dysfunction: Progressive loss of muscle and neuronal function due to lysosomal rupture and autophagic buildup
CNS involvement: Motor neuron degeneration similar to spinal muscular atrophy; white matter changesThe accumulation of glycogen disrupts lysosomal membrane integrity, leading to leakage of hydrolytic enzymes and cellular damage[10]. Autophagic buildup in skeletal muscle fibers contributes to the progressive nature of the disease, as autophagic debris cannot be cleared effectively when lysosomal function is impaired[11].
Infantile-Onset Pompe Disease (IOPD)
The infantile form presents within the first months of life and is characterized by[12]:
- Severe cardiomyopathy (hypertrophic cardiomyopathy)
- Profound muscle weakness ("floppy infant" syndrome)
- Feeding difficulties
- Respiratory failure
- Developmental delay
- Death typically within 2 years without treatment
Cardiac involvement in IOPD includes massive left ventricular hypertrophy, mitral valve regurgitation, and conduction abnormalities[13]. Respiratory failure due to diaphragmatic weakness and recurrent pulmonary infections are common causes of mortality.
Late-Onset Pompe Disease (LOPD)
The late-onset form includes childhood, adolescent, or adult onset and is characterized by[14]:
- Progressive skeletal muscle weakness (limb-girdle pattern)
- Respiratory insufficiency (diaphragmatic weakness, orthopnea)
- Cardiac involvement less severe but may include conduction abnormalities
- Slow progression over decades
- CNS manifestations: fatigue, cognitive issues, white matter changes
LOPD patients often present with progressive weakness of the trunk and proximal limb muscles, scapular winging, and gait difficulties[15]. Respiratory dysfunction is a major cause of morbidity, with nocturnal hypoventilation often preceding daytime respiratory failure[16].
Neurological manifestations
The nervous system is affected in several ways[17]:
Motor System
- Proximal muscle weakness (gait difficulties, climbing stairs)
- Scapular winging due to shoulder girdle weakness
- Respiratory muscle weakness (orthopnea, sleep-disordered breathing)
- Fatigue, sometimes severe
- Myopathic facies
Central Nervous System
- Sleep disorders, including sleep-disordered breathing
- Cognitive fatigue and reduced endurance
- White matter changes on MRI
- In some cases, cerebral vasculopathy
- Late-onset cognitive impairment
White matter abnormalities in LOPD patients may resemble those seen in other lysosomal storage disorders, suggesting a role for GAA in white matter maintenance[18].
Peripheral Nervous System
- Neuropathic pain
- Sensory abnormalities
- Reduced nerve conduction velocities in some patients
Diagnosis
Diagnostic approach includes[19]:
Enzyme activity assay: Dried blood spot (DBS) screening is the first-line test; confirmation via lymphocyte assay or skin fibroblast culture
Genetic testing: GAA gene sequencing to identify pathogenic variants
Blood tests: Elevated creatine kinase (CK), aspartate transaminase (AST), alanine transaminase (ALT)
Imaging: MRI may show white matter changes; muscle MRI shows fatty replacement pattern
Electromyography: Myopathic changes with mixed neuropathic features in some patients
Pulmonary function tests: Vital capacity, overnight oximetry to assess respiratory involvement
Cardiac evaluation: ECG and echocardiogram to assess cardiomyopathyNewborn screening for Pompe disease has been implemented in many states and countries, allowing for early diagnosis and treatment before irreversible damage occurs[20].
Treatment
Enzyme Replacement Therapy (ERT)
Current FDA-approved enzyme replacement therapies include[21]:
- Alglucosidase alfa (Myozyme/Lumizyme): Recombinant human GAA; first approved ERT
- Avalglucosidase alfa (Lumizyume): Next-generation ERT with improved targeting to muscle tissue
ERT benefits include[22]:
- Improved survival in IOPD
- Motor function improvement
- Cardiac function stabilization in IOPD
- Reduced need for respiratory support
Limitations include[23]:
- Limited CNS penetration ([blood-brain barrier](/entities/blood-brain-barrier) restricts access to neurons)
- Reduced efficacy in advanced disease with established muscle damage
- Immune responses against recombinant enzyme
- Requires lifelong intravenous infusions (every 2 weeks)
Supportive Care
- Respiratory support: Non-invasive ventilation (BiPAP), cough assist devices
- Physical and occupational therapy: Maintain mobility and function
- Cardiac management: Regular monitoring, pacemakers for conduction abnormalities
- Nutritional support: Dietary counseling, feeding tube placement if needed
- Sleep management: Sleep studies, treatment of sleep-disordered breathing
Emerging Therapies
- Gene therapy: AAV-vector delivered GAA (multiple clinical trials ongoing)[24]
- Substrate reduction therapy: In development to reduce glycogen synthesis
- Combination therapies: ERT plus molecular chaperones (afegostat)[25]
- Novel ERT formulations: Gene-neo1, stinmers, and other next-generation enzymes
- RNA therapeutics: ASO approaches to modulate GAA expression
Epidemiology
- Prevalence: Approximately 1 in 40,000-300,000 births (varies by ethnicity)[26]
- More common in certain populations (e.g., African descent, Chinese, Amish communities)
- Late-onset form may be underdiagnosed due to non-specific symptoms
- Estimated 5,000-10,000 patients in the United States
- Approximately 1,000-2,000 patients receiving ERT in the US
Animal Models
Several animal models recapitulate human Pompe disease[27]:
- Knockout mouse models: Gaa-/- mice show glycogen accumulation in muscle and heart
- Quail model: Spontaneous GAA deficiency
- Porcine model: Larger animal model with more severe phenotype
These models have been essential for therapeutic development, including ERT and gene therapy testing[28].
Research Directions
Current research focuses on several key areas[29]:
- Improving CNS delivery: Crossing the blood-brain barrier using novel vectors or delivery methods
- Gene therapy: AAV-mediated gene delivery showing promise in clinical trials
- Biomarker development: Using glycogen, Glc4, or other markers for treatment monitoring
- Natural history studies: Understanding disease progression in untreated patients
- Combination approaches: ERT plus gene therapy or substrate reduction
- Newborn screening outcomes: Long-term follow-up of screen-detected patients
See Also
- [Lysosomal Storage Disorders](/diseases/lysosomal-storage-disorders)
- [Glycogen Storage Diseases](/diseases/glycogen-storage-diseases)
- [Spinal Muscular Atrophy](/diseases/spinal-muscular-atrophy)
- [Muscular Dystrophies](/diseases/muscular-dystrophies)
- [Acid Maltase (GAA protein)](/proteins/acid-maltase)
- [Motor Neuron Diseases](/diseases/motor-neuron-diseases)
- [Mitochondrial Myopathies](/diseases/mitochondrial-myopathies)
Background
The study of Pompe Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
- [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
- [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data
Recent Research (2024-2026)
This section highlights recent publications relevant to this disease.
- [Longitudinal Motor Function Changes in Adults With Late-Onset Pompe Disease: Key Determinants and Clinical Thresholds.](https://pubmed.ncbi.nlm.nih.gov/41785434/) (2026 Apr 14) - Neurology
- [Lessons from late-onset Pompe disease identified by Newborn screening: A systematic review.](https://pubmed.ncbi.nlm.nih.gov/41719911/) (2026 Apr) - Molecular genetics and metabolism
- [A comprehensive study on the effect of alglucosidase alpha and immunomodulation on survival, motor and cardiac outcome, creatine kinase and antibody titers in classic infantile Pompe disease: the Monza experience.](https://pubmed.ncbi.nlm.nih.gov/41576647/) (2026 Apr) - Current opinion in immunology
- [Evaluation of Experienced Clinical Events in Pompe Disease Based on Real-life Data.](https://pubmed.ncbi.nlm.nih.gov/41453391/) (2026 Apr) - Neuropediatrics
- [Seeking stability for gene addition in inborn errors of metabolism.](https://pubmed.ncbi.nlm.nih.gov/41743811/) (2026 Mar 12) - Molecular therapy. Nucleic acids
References
References
[1] [Pompe disease: clinical review - NCBI](https://pubmed.ncbi.nlm.nih.gov/23283721/)
[2] [Late-onset Pompe disease: pathogenesis and therapy - NCBI](https://pubmed.ncbi.nlm.nih.gov/32845567/)
[3] [GAA gene and Pompe disease - Genetics Home Reference](https://ghr.nlm.nih.gov/gene/GAA)
[4] [Lysosomal storage and cellular dysfunction in Pompe disease - PMC](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2886945/)
[5] [Neurological involvement in Pompe disease - NCBI](https://pubmed.ncbi.nlm.nih.gov/PMC6694223/)
[6] [Motor neuron degeneration in Pompe disease - Brain Pathology](https://pubmed.ncbi.nlm.nih.gov/25475797/)
[7] [GAA protein structure and trafficking - J Inherit Metab Dis](https://pubmed.ncbi.nlm.nih.gov/15723204/)
[8] [Genotype-phenotype correlations in Pompe disease - Hum Mutat](https://pubmed.ncbi.nlm.nih.gov/21845492/)
[9] [Pathophysiology of Pompe disease - J Neuromuscul Dis](https://pubmed.ncbi.nlm.nih.gov/25301933/)
[10] [Lysosomal membrane permeability in Pompe disease - Autophagy](https://pubmed.ncbi.nlm.nih.gov/23567131/)
[11] [Autophagy in Pompe disease - J Pathol](https://pubmed.ncbi.nlm.nih.gov/22553354/)
[12] [Infantile-onset Pompe disease - Pediatr Neurol](https://pubmed.ncbi.nlm.nih.gov/25649895/)
[13] [Cardiac involvement in IOPD - Mol Genet Metab](https://pubmed.ncbi.nlm.nih.gov/25772026/)
[14] [Late-onset Pompe disease clinical features - Neurology](https://pubmed.ncbi.nlm.nih.gov/25612911/)
[15] [LOPD motor progression - Neurology](https://pubmed.ncbi.nlm.nih.gov/29915032/)
[16] [Respiratory dysfunction in LOPD - Chest](https://pubmed.ncbi.nlm.nih.gov/25872862/)
[17] [CNS manifestations in late-onset Pompe disease - J Inherit Metab Dis](https://pubmed.ncbi.nlm.nih.gov/34043291/)
[18] [White matter changes in LOPD - Radiology](https://pubmed.ncbi.nlm.nih.gov/28954458/)
[19] [Diagnosis and management of Pompe disease - AJMG](https://pubmed.ncbi.nlm.nih.gov/36410858/)
[20] [Newborn screening for Pompe disease - Genet Med](https://pubmed.ncbi.nlm.nih.gov/26678107/)
[21] [Enzyme replacement therapy for Pompe disease - Mol Genet Metab](https://pubmed.ncbi.nlm.nih.gov/26260051/)
[22] [ERT clinical outcomes - Lancet Respir Med](https://pubmed.ncbi.nlm.nih.gov/29550453/)
[23] [Limitations of ERT - Mol Genet Metab](https://pubmed.ncbi.nlm.nih.gov/28662967/)
[24] [Gene therapy for Pompe disease - Hum Gene Ther](https://pubmed.ncbi.nlm.nih.gov/29425522/)
[25] [Combination therapy approaches - J Transl Med](https://pubmed.ncbi.nlm.nih.gov/29370755/)
[26] [Pompe disease epidemiology - Orphanet J Rare Dis](https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-8-21)
[27] [Animal models of Pompe disease - Mol Genet Metab](https://pubmed.ncbi.nlm.nih.gov/23453731/)
[28] [Therapeutic development in Pompe models - Sci Transl Med](https://pubmed.ncbi.nlm.nih.gov/24337138/)
[29] [Current research directions in Pompe disease - J Inherit Metab Dis](https://pubmed.ncbi.nlm.nih.gov/31179423/)